PubAg

Main content area

Elegant pH-Responsive Nanovehicle for Drug Delivery Based on Triazine Dendrimer Modified Magnetic Nanoparticles

Author:
Landarani-Isfahani, Amir, Moghadam, Majid, Mohammadi, Shima, Royvaran, Maryam, Moshtael-Arani, Naimeh, Rezaei, Saghar, Tangestaninejad, Shahram, Mirkhani, Valiollah, Mohammadpoor-Baltork, Iraj
Source:
Langmuir 2017 v.33 no.34 pp. 8503-8515
ISSN:
1520-5827
Subject:
Fourier transform infrared spectroscopy, biocompatibility, blood, bromides, coagulation, confocal laser scanning microscopy, cytotoxicity, dendrimers, drug therapy, flow cytometry, hemagglutination, hemolysis, illicit drugs, light scattering, magnetism, medicine, methotrexate, nanocarriers, nanoparticles, neoplasm cells, scanning electron microscopy, thermogravimetry, transmission electron microscopy, triazines
Abstract:
Owing to properties of magnetic nanoparticles and elegant three-dimensional macromolecule architectural features, dendrimeric structures have been investigated as nanoscale drug delivery systems. In this work, a novel magnetic nanocarrier, generation two (G2) triazine dendrimer modified Fe₃O₄@SiO₂ magnetic nanoparticles (MNP-G2), was designed, fabricated, and characterized by Fourier transform infrared (FT-IR), thermal gravimetric analysis (TGA), vibrating sample magnetometer (VSM), field emission scanning electron microscopy (FE-SEM), transmission electron microscopy (TEM), and dynamic light scattering (DLS). The prepared MNP-G2 nanosystem offers a new formulation that combines the unique properties of MNPs and triazine dendrimer as a biocompatible material for biomedical applications. To demonstrate the potential of MNP-G2, the nanoparticles were loaded with methotrexate (MTX), a proven chemotherapy drug. The MTX-loaded MNP-G2 (MNP-G2/MTX) exhibited a high drug-loading capacity of MTX and the excellent ability for controlled drug release. The cytotoxicity of MNP-G2/MTX using an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide based assay and MCF-7, HeLa, and Caov-4 cell lines revealed that MNP-G2/MTX was more active against the tumor cells than the free drug in a mildly acidic environment. The results of hemolysis, hemagglutination, and coagulation assays confirmed the good blood safety of MNP-G2/MTX. Moreover, the cell uptake and intracellular distribution of MNP-G2/MTX were studied by flow cytometry analysis and confocal laser scanning microscopy (CLSM). This research suggests that MNP-G2/MTX with good biocompatibility and degradability can be selected as an ideal and effective drug carrier in targeted biomedicine studies especially anticancer applications.
Agid:
5796731